Transdermal drug delivery system containing granisetron

摘要

Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer.

主权项

1. A transdermal granisetron delivery system in a matrix form comprising:
granisetron as an active ingredient and a matrix, including:
an adhesive consisting of an acrylate polymer with a hydroxyl group and another acrylate polymer without any functional group in a ratio of 50 to 95:5 to 50; andat least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 (PEG-20) almond glyceride, polyethyleneglycol-12 (PEG-12) palm kernel glyceride, isopropyl myristate and oleyl alcohol,whereingranisetron is contained in an amount of 1 to 6 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system;the transdermal enhancer is contained in an amount of 0.1 to 25 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system andthe transdermal granisetron delivery system has a drug permeation rate of not less than 10 μg/cm2/hr as measured on a hairless mouse's skin.